Loading...
Please wait, while we are loading the content...
Similar Documents
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
| Content Provider | Scilit |
|---|---|
| Author | Byrd, John C. Flynn, Joseph M. Kipps, Thomas J. Boxer, Michael Kolibaba, Kathryn S. Carlile, David J. Fingerle-Rowson, Guenter Tyson, Nicola Hirata, Jamie Sharman, Jeff P. |
| Copyright Year | 2016 |
| Description | Key Points Obinutuzumab monotherapy demonstrates an increased ORR with 2000 mg over 1000 mg, but no difference in progression-free survival. No meaningful difference was observed in the overall safety profile across the 2 treatment arms. |
| Related Links | https://ashpublications.org/blood/article-pdf/127/1/79/1392335/79.pdf |
| Ending Page | 86 |
| Page Count | 8 |
| Starting Page | 79 |
| DOI | 10.1182/blood-2015-03-634394 |
| Journal | Blood |
| Issue Number | 1 |
| Volume Number | 127 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2016-01-07 |
| Access Restriction | Open |
| Subject Keyword | Hematology Oncology Cll Antibody Lymphocytic Leukemia Chronic Lymphocytic Obinutuzumab Monotherapy Randomized Phase Cd20 Complete Response Journal: Blood (Vol- 23, Issue- 1) |
| Content Type | Text |
| Resource Type | Article |